ZENPEP
Clinical safety rating: caution
Comprehensive clinical and safety monograph for ZENPEP (ZENPEP).
ZenPep (pancrelipase) is a pancreatic enzyme replacement therapy containing lipase, protease, and amylase. It hydrolyzes fats to monoglycerides, glycerol, and fatty acids; proteins to amino acids and peptides; and starch to dextrins and short-chain sugars, thereby facilitating digestion in patients with exocrine pancreatic insufficiency.
| Metabolism | Pancrelipase acts locally in the gastrointestinal tract and is not absorbed systemically in significant amounts; thus, it does not undergo hepatic metabolism via CYP450 enzymes. |
| Excretion | ZenPep (pancrelipase) is not absorbed systemically; it acts locally in the gastrointestinal tract. No significant systemic absorption occurs; therefore, excretion is primarily fecal as unabsorbed enzymes and degradation products. Renal excretion is negligible. |
| Half-life | Not applicable; ZenPep is not absorbed systemically and has no measurable plasma half-life. Clinical effect is directly related to local enzyme activity in the duodenum. |
| Protein binding | Not applicable; ZenPep is not absorbed systemically, so protein binding is irrelevant. The enzymes are proteins themselves but act locally. |
| Volume of Distribution | Not applicable; ZenPep is not absorbed, so Vd is not defined. |
| Bioavailability | Bioavailability is negligible (<1%) due to minimal systemic absorption; the drug acts locally in the gastrointestinal tract. |
| Onset of Action | Onset of action occurs within 30–60 minutes after oral administration, corresponding to the time required for the enteric-coated microspheres to dissolve in the duodenum and release active lipase, amylase, and protease. |
| Duration of Action | Duration of action is approximately 1–2 hours postprandially, correlating with the time enzymes remain active in the duodenum to digest nutrients. Dosing is typically with each meal or snack. |
500 lipase units/kg per meal orally, with snacks at half the meal dose; maximum 2500 lipase units/kg per meal or 10,000 lipase units/kg per day.
| Dosage form | CAPSULE, DELAYED RELEASE |
| Renal impairment | Not required; ZenPep is not systemically absorbed. No dose adjustment based on GFR. |
| Liver impairment | No adjustment needed; ZenPep acts locally in the gastrointestinal tract without systemic absorption. |
| Pediatric use | Same weight-based dosing as adults: 500 lipase units/kg per meal, up to 2500 units/kg per meal; for infants, dose per 100 mL expressed milk or per feeding based on fat content. |
| Geriatric use | No specific dose adjustment; use lowest effective dose and monitor for gastrointestinal adverse effects. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for ZENPEP (ZENPEP).
| Breastfeeding | Excretion in human milk unknown; no M/P ratio available. Caution should be exercised when administered to a nursing woman. Consider developmental and health benefits of breastfeeding along with mother's clinical need. |
| Teratogenic Risk | No adequate and well-controlled studies in pregnant women. Animal reproduction studies have not been conducted. Based on mechanism of action (pancreatic enzymes), teratogenic risk is considered low; however, use only if clearly needed. |
| Fetal Monitoring |
■ FDA Black Box Warning
None.
| Serious Effects |
["Known hypersensitivity to any ingredient of pancrelipase (including pork proteins)","Acute pancreatitis","Acute flare of chronic pancreatitis"]
| Precautions | ["Fibrosing colonopathy reported, especially at high doses; do not exceed recommended dose","Potential for allergic reactions (e.g., anaphylaxis, urticaria) in patients with hypersensitivity to pork proteins","Risk of hyperuricemia, particularly with high doses; monitor uric acid levels if symptoms occur","Cases of rapid eye movement and abnormal behavior reported; monitor for signs","Potential for malnutrition if dosing is inadequate","Caution in patients with gout, renal impairment, or hyperuricemia"] |
Loading safety data…
| Standard prenatal care; no specific monitoring required beyond routine pregnancy management. |
| Fertility Effects | No known effects on fertility based on limited data; no studies on reproductive toxicity conducted. |